Examining the Role of Gluten and Wheat in Irritable Bowel Syndrome: Insights from a Double-Blind, Sham-Controlled Crossover Trial

Highlight

This randomized, double-blind, sham-controlled crossover trial investigated the symptomatic effects of gluten and wheat compared to a gluten-free sham challenge in IBS patients who had previously reported improvement on a gluten-free diet. Findings demonstrated no significant difference in symptom worsening between gluten, wheat, and sham challenges, suggesting that patient expectations significantly influence symptom perception. Identifying true gluten or wheat-sensitive IBS patients is critical for targeted dietary recommendations and destigmatization.

Study Background and Disease Burden

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, significantly impairing quality of life. Many IBS patients self-report symptom exacerbation related to gluten or wheat intake and adopt gluten-free or wheat-free diets in search of relief. However, the accuracy of these self-reports and the role of gluten or wheat in symptom generation remain controversial. Misattribution of symptoms to gluten or wheat can lead to unnecessarily restrictive diets, stigmatization of these staple foods, and potential nutritional deficiencies. Thus, high-quality clinical trials are needed to rigorously evaluate the effect of gluten and wheat intake on symptom severity in IBS patients with perceived gluten sensitivity.

Study Design

This study was a randomized, double-blind, sham-controlled crossover trial conducted at McMaster University Medical Centre, ON, Canada. Eligible participants were adults aged 18 years or older, meeting Rome IV criteria for IBS, who had followed a gluten-free diet for at least three weeks and reported symptomatic improvement. Twenty-nine participants were randomly assigned to six different sequences of wheat, gluten, and sham challenges administered via cereal bars. Each challenge period lasted seven days, separated by 14-day washout intervals. The sham challenge used cereal bars free of gluten and wheat but matched in appearance, taste, and smell to maintain blinding. The primary outcome was a worsening of IBS symptoms by at least 50 points on the IBS Symptom Severity Score (IBS-SSS) after each dietary challenge. Safety and adverse events were monitored throughout the trial. The trial is registered with ClinicalTrials.gov (NCT03664531).

Key Findings

Out of 101 screened individuals, 29 were enrolled and randomized; 28 completed all three dietary challenge phases. Analysis showed no statistically significant difference in symptom worsening frequency between wheat (39%), gluten (36%), and sham (29%) challenges. The risk differences compared to sham were 0.11 (95% CI -0.16 to 0.35) for wheat and 0.07 (95% CI -0.19 to 0.32) for gluten, indicating no clear excess symptom trigger by gluten or wheat over sham. Adverse events occurred similarly across challenges, with high overall incidence (~93%) but no severe adverse events reported. These results suggest that reported sensitivity to gluten or wheat in this subset of IBS patients may be influenced predominantly by expectation or placebo/nocebo effects.

Expert Commentary

This study provides valuable evidence that challenges the common assumption that gluten or wheat directly worsens symptoms in the majority of IBS patients who believe they are gluten-sensitive. The rigorous double-blind, sham-controlled crossover design and identical appearance and taste of challenge bars strengthen the reliability of the findings. Nonetheless, a subset of patients may still represent true gluten or wheat-sensitive IBS, highlighting the need for refined diagnostic criteria and biomarkers to distinguish these individuals. The high adverse event rate across all challenges highlights the complexity of IBS symptom perception and the impact of psychological factors. Future research may explore mechanistic pathways such as immune activation, microbiome alterations, and central nervous system modulation that contribute to symptom generation in IBS and food sensitivities.

Conclusion

This clinical trial demonstrates that in IBS patients with self-perceived gluten sensitivity, the symptomatic response to gluten and wheat is indistinguishable from gluten- and wheat-free sham challenges. This underscores the significant role of patient expectations in symptom manifestation and indicates that broad gluten or wheat restrictions may not benefit most IBS patients. Personalized dietary recommendations focused on identifying true gluten or wheat-sensitive patients while avoiding unnecessary food stigmatization are essential for effective clinical management. Enhanced patient education and clinician awareness may improve management strategies and patient quality of life.

References

Seiler CL, Rueda GH, Miranda PM, Nardelli A, Borojevic R, Hann A, Rahmani S, De Souza R, Caminero A, Curella V, Neerukonda M, Vanner S, Schuppan D, Moayyedi P, Collins SM, Verdu EF, Pinto-Sanchez MI, Bercik P. Effect of gluten and wheat on symptoms and behaviours in adults with irritable bowel syndrome: a single-centre, randomised, double-blind, sham-controlled crossover trial. Lancet Gastroenterol Hepatol. 2025 Sep;10(9):794-805. doi: 10.1016/S2468-1253(25)00090-1. Epub 2025 Jul 21. PMID: 40706614.